2020
CHANGES IN DIRECTOR’S INTEREST (SECTION 219 OF CA 2016) – MR DAVID CHOO BOON LEONG
NOVA MSC BERHAD 19 Mar 2020 Particulars of Director Name MR DAVID CHOO BOON LEONG Descriptions(Class) Ordinary Share Details of changes No Date of change No of securities Type of transaction Nature of Interest 1 17/03/2020 300,000 Acquired Direct Interest Name of registered holder David Choo Boon Leong Description of “Others” Type of Transaction Consideration (if any) Circumstances by…
SELENA+ OBTAINS APPROVAL FOR MARKET ACCESS IN EU
9 Mar 2020 – EyRIS is pleased to announce that SELENA+, a deep learning AI system designed to detect diabetic retinopathy, glaucoma-suspect and age-related macular degeneration, jointly invented by clinicians and scientists from Singapore Eye Research Institute (SERI) and NUS School of Computing has received CE Marking certification. EyRIS is a start-up company established to commercialise SELENA+, which was trained…
SELENA+ HIGHLIGHTED AS PART OF NATIONAL STRATEGY TO DELIVER QUALITY CARE
5 Mar 2020 – In a debate on Singapore Health Ministry’s budget for the year, Minister Gan Kim Yong shared the plans to leverage technologies such as artificial Intelligence and robotics to deliver quality care in the nation’s ageing and growing population. One example highlighted by Minister Gan was SELENA+, a deep learning system (DLS) to check for diabetic retinopathy,…
Quarterly rpt on consolidated results for the financial period ended 31/12/2019
NOVA MSC BERHAD 27 Feb 2020
NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) : FUND RAISING NOVA MSC BERHAD (“NOVAMSC” OR THE “COMPANY”) (I) RIGHTS ISSUE; (II) PLACEMENT; AND (III) AMENDMENTS (COLLECTIVELY REFERRED TO AS THE “CORPORATE EXERCISES”)
NOVA MSC BERHAD 25 Feb 2020 We refer to the Company’s announcements made on 25 November 2019, 3 December 2019, 13 December 2019, 24 December 2019, 26 December 2019, 17 January 2020, 12 February 2020 and 13 February 2020 in relation to the Corporate Exercises (“Announcements”). For consistency purposes, the abbreviations used in this announcement shall carry the same meaning…
NOVAMSC – Notice of Rights Entitlement
NOVA MSC BERHAD 13 Feb 2020 RENOUNCEABLE RIGHTS ISSUE OF UP TO 2,094,173,136 NEW IRREDEEMABLE CONVERTIBLE PREFERENCE SHARES (“RIGHTS ICPS”) IN NOVA MSC BERHAD (“NOVAMSC”) AT THE ISSUE PRICE OF RM0.01 PER RIGHTS ICPS ON THE BASIS OF 8 RIGHTS ICPS FOR EVERY 3 EXISTING ORDINARY SHARES IN NOVAMSC HELD BY THE ENTITLED SHAREHOLDERS AT 5.00 P.M. ON 26 FEBRUARY…
NOVAMSC – Notice of Rights Entitlement
NOVA MSC BERHAD 13 Feb 2020 RENOUNCEABLE RIGHTS ISSUE OF UP TO 2,094,173,136 NEW IRREDEEMABLE CONVERTIBLE PREFERENCE SHARES (“RIGHTS ICPS”) IN NOVA MSC BERHAD (“NOVAMSC”) AT THE ISSUE PRICE OF RM0.01 PER RIGHTS ICPS ON THE BASIS OF 8 RIGHTS ICPS FOR EVERY 3 EXISTING ORDINARY SHARES IN NOVAMSC HELD BY THE ENTITLED SHAREHOLDERS AT 5.00 P.M. ON 26 FEBRUARY…
NOVAMSC – Notice of Rights Entitlement (Ratio)
NOVA MSC BERHAD 13 Feb 2020 RENOUNCEABLE RIGHTS ISSUE OF UP TO 2,094,173,136 NEW IRREDEEMABLE CONVERTIBLE PREFERENCE SHARES (“RIGHTS ICPS”) IN NOVA MSC BERHAD (“NOVAMSC”) AT THE ISSUE PRICE OF RM0.01 PER RIGHTS ICPS ON THE BASIS OF 8 RIGHTS ICPS FOR EVERY 3 EXISTING ORDINARY SHARES IN NOVAMSC HELD BY THE ENTITLED SHAREHOLDERS AT 5.00 P.M. ON 26 FEBRUARY…
Important Relevant Dates for Renounceable Rights
NOVA MSC BERHAD 12 Feb 2020 Entitlement subject Important Relevant Dates for Renounceable Rights Description RENOUNCEABLE RIGHTS ISSUE OF UP TO 2,094,173,136 NEW IRREDEEMABLE CONVERTIBLE PREFERENCE SHARES (“RIGHTS ICPS”) IN NOVA MSC BERHAD (“NOVAMSC”) AT THE ISSUE PRICE OF RM0.01 PER RIGHTS ICPS ON THE BASIS OF 8 RIGHTS ICPS FOR EVERY 3 EXISTING ORDINARY SHARES IN NOVAMSC HELD BY…
Rights Issue
NOVA MSC BERHAD 12 Feb 2020 Entitlement subject Rights Issue Type Renounceable Entitlement description RENOUNCEABLE RIGHTS ISSUE OF UP TO 2,094,173,136 NEW IRREDEEMABLE CONVERTIBLE PREFERENCE SHARES (“RIGHTS ICPS”) IN NOVA MSC BERHAD (“NOVAMSC”) AT THE ISSUE PRICE OF RM0.01 PER RIGHTS ICPS ON THE BASIS OF 8 RIGHTS ICPS FOR EVERY 3 EXISTING ORDINARY SHARES IN NOVAMSC HELD BY THE…
EYRIS CO-FOUNDER DISCUSSES THE FUTURE OF AI IN OPHTHALMOLOGY
Jan 2020 – In the article published by the The Ophthalmologist – Ophthalmic Frontiers: AI, four recognized artificial intelligence and deep learning gurus discuss the use of these advanced technologies in eye care – and predict where they may take us next. We are pleased to share that Dr Daniel Ting, an EyRIS co-founder is one of the selected experts…